Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
sonrotoclax · venetoclax · BCL-2 · G101V mutation · venetoclax resistance · BCL2 inhibitor · chronic lymphocytic leukemia · hematologic malignancy · apoptosis · Pro-apoptotic proteins · P2 pocket · Crystal structure · Drug resistance · BCL2 variants · binding mode · tumor growth inhibition · second-generation inhibitor
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459